Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Exelixis (EXEL) is highlighted as a promising growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 28.3%, with projected EPS growth of 31.8% this year, surpassing the industry average of 19.8% [5] - Exelixis has achieved a year-over-year cash flow growth of 135.6%, significantly higher than the industry average of -4.5% [6] Group 2: Financial Metrics - Earnings growth is crucial for attracting investor attention, with double-digit growth being particularly favorable [4] - The annualized cash flow growth rate for Exelixis over the past 3-5 years is 10.8%, compared to the industry average of 3.7% [7] - There has been a positive trend in earnings estimate revisions for Exelixis, with a 1.3% increase in the current-year earnings estimates over the past month [9] Group 3: Investment Positioning - Exelixis has earned a Growth Score of A and a Zacks Rank 2 due to positive earnings estimate revisions, positioning it well for potential outperformance [11]

On July 11, 2025, Andrew Hill Investment Advisors, Inc. disclosed it sold out its entire Johnson & Johnson (JNJ -0.60%) position, totaling $6.31 million in trades.What happenedAccording to a July 10, 2025 SEC filing, the firm exited its entire position in Johnson & Johnson during Q2 2025, selling all 38,037 shares for $6,308,131 in reported transaction value. Andrew Hill Investment Advisors no longer holds JNJ shares as of June 30, 2025, based on 13F disclosures.What else to knowThe sale represents a full e ...

Key Takeaways GSK's Arexvy filing seeks FDA approval for use in high-risk adults under age 50. Late-stage trial data showed Arexvy's safety matched results from previous vaccine studies. Arexvy's sales dropped 51% in 2024 amid tighter U.S. guidelines and rising vaccine competition.GSK plc (GSK) announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision is expected in the first ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 14th:Eledon Pharmaceuticals, Inc. (ELDN) : This clinical stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 23.8% over the last 60 days.Eledon’s shares gained 22.2% over the past month compared with the S&P 500’s advance of 3.8%. The company possesses a Momentum Score of A.KDDI Corporation (KDDIY) : This Japanese teleco ...

Tylenol parent Kenvue Inc (NASDAQ:KVUE) is up 1.4% to trade at $21.64, after the company fired its CEO Thibaut Mongon amid efforts to revamp performance. Mongon also stepped down from his position on the board, as Kirk Perry was named interim CEO. This marks the second C-suite shakeup for Kenvue this year, after Chief Financial Officer (CFO) Paul Ruh was replaced with Amit Banati in May. The company also said tariffs could create a negative impact of up to $150 million.KVUE is eyeing a fourth-straight win, ...

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executiv ...

Bain Capital has agreed to make an investment in PCI Pharma Services, a drug services provider that helps assemble and package medicines https://t.co/KK8mEiFPx6 ...

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 billion, representing an increase of 6.7% year over year.The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahea ...

CHONGQING, CHINA - JULY 13: In this photo illustration, a smartphone displaying the logo of Johnson ... More & Johnson (NYSE: JNJ), a leading American multinational corporation known for pharmaceuticals, medical devices, and consumer health products, is held in front of a screen showing the company's latest stock market chart on July 13, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty Images Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. ...

Group 1 - Momentum investors focus on "buying high and selling higher" rather than traditional strategies of buying low and waiting for recovery [1] - Fast-moving trending stocks can lose momentum if their future growth does not justify their high valuations, leading to potential downside risks for investors [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, with tools like the Zacks Momentum Style Score aiding in identifying such stocks [3] Group 2 - Fortress Biotech (FBIO) has shown a price increase of 2.2% over the past four weeks, indicating growing investor interest [4] - FBIO has gained 23.5% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe, with a beta of 1.75 indicating high volatility [5] - FBIO has a Momentum Score of B, suggesting it is an opportune time to invest in the stock [6] Group 3 - An upward trend in earnings estimate revisions has contributed to FBIO earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects [7] - FBIO is trading at a Price-to-Sales ratio of 0.97, indicating it is reasonably valued at 97 cents for each dollar of sales [7] - FBIO appears to have significant growth potential while maintaining a fast pace, alongside other stocks that meet similar criteria [8] Group 4 - There are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [9] - The effectiveness of stock-picking strategies can be backtested using tools like the Zacks Research Wizard, which includes successful strategies [10]